glp-1 agonist consultation process American Society for Gastrointestinal Endoscopy position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors Indications for GLP-1/GIP RA Summary

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

For more details read about our editorial process.

doi: 10.3390/cells9071687 68 BartelsALWillemsenATDoorduinJde VriesEFDierckxRALeendersKL

The risk of developing IIH increases significantly with increasing body mass index (BMI), or following recent weight gain (3) and can go into remission with weight loss (5)

doi: 10.1016/j.cmet.2018.03.001 40 KahlesFMeyerCMllmannJDieboldSFindeisenHMLebherzCet al